Form 4 for IDXX Idexx Laboratories
Accepted 2021-12-01 00:00:00 ET · period of report 2021-11-29 · accession 0001567619-21-021392 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-01 | 2021-11-29 | IDXX | POLEWACZYK JAMES F | EVP | S - Sale | $633.00 | -4,595 | 14.8K | -24% | -$2.91M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-29 | S | D | 4,595 | $633.00 | 14,818.28 | D | — | — | (F1) Updated to correct a scrivener's error in the Form 4 filed on August 25, 2021, which inadvertently reported the total amount of beneficially owned securities following the reported transaction as 19,494.2845 instead of 19,404.2845. Also includes 9 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2021. |